

**Supplementary Information to
Polyoxovanadates inhibition of *Escherichia coli* growth shows a reverse
correlation with Ca²⁺-ATPase inhibition**

Dorinda Silva^{1,2}, Gil Fraqueza^{3,4}, Ricardo Lagoa^{1,2}, Anjana Anandan Vannathan⁵, Sib Sankar Mal^{5*} and
Manuel Aureliano^{4,6*}

¹ESTG, Polytechnic Institute of Leiria, Portugal; ² UCIBIO, Faculty of Science and Technology, University NOVA of Lisbon, Portugal; ³ISE, University of Algarve, 8005-139 Faro, Portugal; ⁴CCMar, University of Algarve, 8005-139 Faro, Portugal; ⁵Department of Chemistry, National Institute of Technology Karnataka, Mangalore 575025, Karnataka, India; ⁶FCT, University of Algarve, 8005-139 Faro, Portugal




Fig. S1. FT-IR spectrum of the $K_5Mn^{IV}V_{11}O_{32}$ manganese polyoxovanadate compound.

IR data (solid/KBr pellet, cm^{-1}): $K_5Mn^{IV}V_{11}O_{32}$: 982, 943 (vs) (V=O_{term}), 837, 589, 560 (m) (V-O-V_{as}), 731 (s).




Fig. S2. FT-IR spectrum of the $K_7Mn^{IV}V_{13}O_{38}$ manganese polyoxovanadate compound.

IR data (solid/KBr pellet, cm^{-1}): 964(s) ($V=O_{term}$), 839, 812, 578, 524 ($V-O-V_{as}$), 747 (s) ($Mn-O-V$).




Figure S3. UV/vis spectra of decavanadate (V10, 0.05 mM) and vanadate (V1, 0.5 mM) after 0 and 3 hours incubation in water (left panel) as well as on the microbiological medium (right panel).




Figure S4. Decavanadate V_{10} concentration 1 mM (panel A) and vanadate V_1 concentration 10 mM (panel B), in culture medium LB, after 24 hours incubation at 37°C.




Figure S5. Lineweaver-Burk plot of Ca²⁺-ATPase activity in the absence (blue) and in the presence (orange) of 15 μM of the polyoxometalate MnV₁₁, used for determining the type of enzyme inhibition. The POV presented a mixed type of inhibition. Data are plotted as means ± SD. The results shown are the average of triplicate experiments.

Table S1. Antibacterial activity (MIC) of POMs alone, POM-hybrids and nanocomposites against *E. coli*.

POM/POM-hybrid	MIC ($\mu\text{g/ml}$)	Ref.
Polyoxometalate alone:		
[V ₁₀ O ₂₈] ⁶⁻	50	48
[P ₅ W ₃₀] ¹⁴⁻	>265	62
[P ₂ W ₁₅ V ₃] ⁶⁻	>265	62
[P ₂ O ₇ Mo ₁₈] ⁶⁻	>265	62
[As ₂ Mo ₁₈] ⁶⁻	>265	62
Organic-inorganic-POM:		
organoantimony-polyoxotungstate:		
[(PhSb ^{III}) ₄ (A- α -Ge ^{IV} W ₉ O ₃₄) ₂] ¹²⁻	80	45
[(PhSb ^{III}) ₄ (A- α -PVW ₉ O ₃₄) ₂] ¹⁰⁻	110	45
[{2-(Me ₂ NCH ₂ C ₆ H ₄)Sb ^{III} } ₃ (B- α -As ^{III} W ₉ O ₃₃)] ³⁻	130	45
[(PhSb ^{III}) ₂ {Na(H ₂ O)}As ^{III} ₂ W ₁₉ O ₆₇] ¹¹⁻	500	46
[(PhSb ^{III}) ₂ As ^{III} ₂ W ₁₉ O ₆₇] ¹⁰⁻	250	46
[(PhSb ^{III}) ₃ (B- α -As ^{III} W ₉ O ₃₃) ₂] ¹²⁻	125	46
Quinolone-based drug-POM:		
[Co ^{II} (C ₁₉ FH ₂₂ N ₃ O ₄) ₃][C ₁₉ FH ₂₃ N ₃ O ₄][HSiW ₁₂ O ₄₀]	2.4	47
Nanocomposite:		
Bamboo charcoal-POM:		
BC/POM	4	50
Polymer-POM:		
PVA/PEI-POM:		
PVA-PEI-H ₅ PV ₂ Mo ₁₀ O ₄₀	2	49
Chitosan-POM:		
CTS-Ca ₃ V ₁₀ O ₂₈	12.5	48
Polyoxometalate ionic liquids:		
[N(C ₆ H ₁₃) ₄] ₈ [\mathbf{\alpha-SiW_{11}O_{39}}]	1000	51
[N(C ₇ H ₁₅) ₄] ₈ [\mathbf{\alpha-SiW_{11}O_{39}}]	25	51
[N(C ₈ H ₁₇) ₄] ₈ [\mathbf{\alpha-SiW_{11}O_{39}}]	50	51